Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 22,503 matching trials from the live ClinicalTrials.gov search.

Filters: Houston, Texas Clear all

Conditions: Breast Cancer
Interventions: Letrozole, Placebo; Drug · Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 35 Years to 120 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2013
U.S. locations: 5
States / cities: Boston, Massachusetts • Philadelphia, Pennsylvania • Houston, Texas

Conditions: Advanced Cancer
Interventions: Sirolimus, Cetuximab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Infertility, In Vitro Maturation of Oocytes, Assisted Reproduction Technologies
Interventions: CAPA-IVM; Device
Lead sponsor: Inception Fertility Research Institute, LLC; Industry
Eligibility: 18 Years to 37 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Seborrheic Dermatitis
Interventions: Roflumilast Foam, Vehicle Foam; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 9 Years and older
Enrollment: 457 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 43
States / cities: Scottsdale, Arizona • Encinitas, California • San Diego, California + 37 more

Conditions: Breastfeeding
Interventions: Proactive assignment to attend a breastfeeding clinic; Behavioral
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Female only
Enrollment: 522 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Dermatitis, Atopic
Interventions: Dupilumab, JNJ-95475939, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 13
States / cities: Fountain Valley, California • Los Angeles, California • Alpharetta, Georgia + 10 more

Conditions: Tumors
Interventions: BSI-201 (iniparib), irinotecan; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 3
States / cities: New Haven, Connecticut • Houston, Texas • San Antonio, Texas

Conditions: Cluster Headache
Interventions: Vitamin D, multivitamin, Placebo; Dietary Supplement
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 70 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Malignant Glioma
Interventions: CDX-110 with GM-CSF, Temozolomide; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 34
States / cities: Orange, California • San Francisco, California • Stanford, California + 22 more

Conditions: Leukemia
Interventions: Rituximab, Imatinib, Cyclophosphamide, Doxorubicin, Mesna, VSLI, Solu-Medrol, Methotrexate, Ara-C, G-CSF, Pegfilgrastim, Dexamethasone; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Impotence
Interventions: sildenafil citrate, placebo for sildenafil citrate; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 20
States / cities: Huntsville, Alabama • San Diego, California • Aurora, Colorado + 17 more

Conditions: Chronic Hepatitis B
Interventions: telbivudine or lamivudine; Drug
Lead sponsor: Novartis; Industry
Eligibility: 16 Years to 70 Years
Timeline: Started 2003
U.S. locations: 5
States / cities: Los Angeles, California • Orange, California • San Diego, California + 2 more

Conditions: Staphylococcus Aureus
Interventions: Arm 1. Routine Care (Mupirocin/CHG), Arm 2. Iodophor/CHG Decolonization; Drug
Lead sponsor: Harvard Pilgrim Health Care; Other
Eligibility: Not listed
Enrollment: 353,323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 137
States / cities: Riverside, California • San Jose, California • Thousand Oaks, California + 103 more

Conditions: Type 1 Diabetes, Obesity, Overweight
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 18
States / cities: Bonita, California • Escondido, California • Newport Beach, California + 15 more

Conditions: Systemic Infections
Interventions: CAZ-AVI; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 3 Months to 17 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 10
States / cities: Little Rock, Arkansas • Orange, California • San Diego, California + 7 more

Conditions: Ischemia, Retinal Vein Occlusion, Pathologic Processes, Retinal Diseases, Eye Diseases
Interventions: ranibizumab; Drug
Lead sponsor: David M. Brown, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Depression, Tobacco Use Disorder
Interventions: Behavioral Activation Therapy, Discussion, Health Education, Questionnaire Administration, Tobacco Cessation Counseling; Behavioral · Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Anemia
Interventions: methoxy polyethylene glycol-epoetin beta, epoetin alfa, darbepoetin alfa; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 78
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Netarsudil Ophthalmic Solution 0.02%; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 22
States / cities: Huntington Beach, California • Laguna Hills, California • Petaluma, California + 18 more

Conditions: Neoplasms, Breast
Interventions: Lapatinib, Trastuzumab, Aromatase Inhibitors (AIs); Drug · Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 3
States / cities: Mobile, Alabama • Boston, Massachusetts • Houston, Texas

Conditions: Neuromuscular Blockade
Interventions: Sugammadex 2 mg/kg ABW, Sugammadex 2 mg/kg IBW, Sugammadex 4 mg/kg ABW, Sugammadex 4 mg/kg IBW, Neostigmine + Glycopyrrolate, Rocuronium or Vecuronium; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 13
States / cities: Sacramento, California • Miami, Florida • Kansas City, Kansas + 9 more

Conditions: Malignant Neoplasm
Interventions: Cixutumumab, Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 2
States / cities: Detroit, Michigan • Houston, Texas

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 729 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 40
States / cities: Gold River, California • Clearwater, Florida • DeBary, Florida + 31 more

Conditions: Metastatic Cancer, Epithelial Tumor
Interventions: NG-641; Biological
Lead sponsor: Akamis Bio; Industry
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 6
States / cities: Los Angeles, California • Santa Barbara, California • Celebration, Florida + 3 more

Search by objective public record fields.

Letrozole in Preventing Breast Cancer in Postmenopausal Women

Sirolimus and Cetuximab in Advanced Malignancies

Aspire In Vitro Maturation Study

Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)

Hospital-based Paraprofessional Lactation Clinic

A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)

Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors

High Dose Vitamin D Plus Multivitamin in the Prevention of Cluster Headache

Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme

Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia

Assessment Of Sildenafil On Erectile Function And Intercourse Satisfaction And To Validate A New Subject Questionnaire

A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B

Mupirocin-Iodophor ICU Decolonization Swap Out Trial

A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections

Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)

A Behavioral Activation Prenatal and Postpartum Intervention for Depressed Pregnant Smokers

A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.

Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting

Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer

Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146)

Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector